Skip to main content
SpringerLink
Log in

Kolorektalkarzinom: Längeres Überleben bei Kombination mit Cetuximab

  • Literatur kompakt_Gastrointestinale Tumoren
  • Published:
Im Focus Onkologie Aims and scope

In der FIRE-3-Studie wurde bei Patienten mit metastasiertem Kolorektalkarzinom (mCRC) die Wirksamkeit einer Kombination von FOLFIRI plus Cetuximab mit FOLFIRI plus Bevacizumab in der First-Line verglichen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Heinemann V et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065-75.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Barbara Kreutzkamp

Authors
  1. Barbara Kreutzkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kreutzkamp, B. Kolorektalkarzinom: Längeres Überleben bei Kombination mit Cetuximab. Im Focus Onkologie 17, 24 (2014). https://doi.org/10.1007/s15015-014-1487-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-1487-1

Search

Navigation